Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 7
1981 5
1982 7
1983 13
1984 16
1985 24
1986 13
1987 16
1988 38
1989 72
1990 90
1991 96
1992 107
1993 97
1994 119
1995 137
1996 131
1997 123
1998 122
1999 118
2000 128
2001 117
2002 125
2003 106
2004 109
2005 116
2006 119
2007 113
2008 113
2009 118
2010 117
2011 117
2012 130
2013 124
2014 127
2015 131
2016 102
2017 97
2018 83
2019 105
2020 105
2021 118
2022 86
2023 96
2024 24

Text availability

Article attribute

Article type

Publication date

Search Results

3,763 results

Results by year

Filters applied: . Clear all
Page 1
LBA02-09 EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-risk Biochemically Recurrent Prostate Cancer.
[No authors listed] [No authors listed] J Urol. 2023 Jul;210(1):224-226. doi: 10.1097/JU.0000000000003518. Epub 2023 May 2. J Urol. 2023. PMID: 37119051 Clinical Trial.
METHODS: EMBARK is a randomized, phase 3 study of pts with BCR considered high-risk: PSA doubling time 9 months and PSA 2 ng/mL above nadir post-radiotherapy (RT) or 1 ng/mL after radical prostatectomy (RP) postoperative RT. Pts were randomized (1:1:1) to enza 160 mg/day + leu
METHODS: EMBARK is a randomized, phase 3 study of pts with BCR considered high-risk: PSA doubling time 9 months and PSA 2 ng/mL above nadir …
Leuprolide acetate: a drug of diverse clinical applications.
Wilson AC, Meethal SV, Bowen RL, Atwood CS. Wilson AC, et al. Expert Opin Investig Drugs. 2007 Nov;16(11):1851-63. doi: 10.1517/13543784.16.11.1851. Expert Opin Investig Drugs. 2007. PMID: 17970643 Review.
As its basic mechanism of action, leuprolide acetate suppresses gonadotrope secretion of luteinizing hormone and follicle-stimulating hormone that subsequently suppresses gonadal sex steroid production. In addition, leuprolide acetate is presently being tested for t …
As its basic mechanism of action, leuprolide acetate suppresses gonadotrope secretion of luteinizing hormone and follicle-stimulating …
Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial.
Lopes RD, Higano CS, Slovin SF, Nelson AJ, Bigelow R, Sørensen PS, Melloni C, Goodman SG, Evans CP, Nilsson J, Bhatt DL, Clarke NW, Olesen TK, Doyle-Olsen BT, Kristensen H, Arney L, Roe MT, Alexander JH; PRONOUNCE Study Investigators. Lopes RD, et al. Circulation. 2021 Oct 19;144(16):1295-1307. doi: 10.1161/CIRCULATIONAHA.121.056810. Epub 2021 Aug 30. Circulation. 2021. PMID: 34459214 Free PMC article. Clinical Trial.
A major adverse cardiovascular event occurred in 15 (5.5%) patients assigned to degarelix and 11 (4.1%) patients assigned to leuprolide (hazard ratio, 1.28 [95% CI, 0.59-2.79]; P=0.53). CONCLUSIONS: PRONOUNCE (A Trial Comparing Cardiovascular Safety of Degarelix Versus …
A major adverse cardiovascular event occurred in 15 (5.5%) patients assigned to degarelix and 11 (4.1%) patients assigned to leuprolide
Relugolix: A Review in Advanced Prostate Cancer.
Shirley M. Shirley M. Target Oncol. 2023 Mar;18(2):295-302. doi: 10.1007/s11523-022-00944-4. Epub 2023 Jan 18. Target Oncol. 2023. PMID: 36652173 Free PMC article. Review.
In the pivotal phase III HERO trial in men with advanced prostate cancer, once-daily oral relugolix (with a loading dose on day 1) led to a sustained castration rate over 48 weeks of treatment of > 90%, a rate that was non-inferior to that provided by intramuscular leuproli
In the pivotal phase III HERO trial in men with advanced prostate cancer, once-daily oral relugolix (with a loading dose on day 1) led to a …
Gonadotropin-releasing hormone agonists in prostate cancer: A comparative review of efficacy and safety.
Raja T, Sud R, Addla S, Sarkar KK, Sridhar PS, Talreja V, Jain M, Patil K. Raja T, et al. Indian J Cancer. 2022 Mar;59(Supplement):S142-S159. doi: 10.4103/ijc.IJC_65_21. Indian J Cancer. 2022. PMID: 35343198 Free article. Review.
However, goserelin has shown better efficacy in maintaining T levels 50 ng/dL compared with leuprolide. The incidences of T escape are lower with goserelin and leuprolide than buserelin. ...In neoadjuvant setting, when only goserelin was used, the 10-year overall su …
However, goserelin has shown better efficacy in maintaining T levels 50 ng/dL compared with leuprolide. The incidences of T escape ar …
Confounders?
Taskin O, Kursun S, Simsek M, Trak B. Taskin O, et al. Fertil Steril. 2001 Oct;76(4):850-2. doi: 10.1016/s0015-0282(01)02072-6. Fertil Steril. 2001. PMID: 11680434 Free article. No abstract available.
Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment.
Wallach JD, Deng Y, McCoy RG, Dhruva SS, Herrin J, Berkowitz A, Polley EC, Quinto K, Gandotra C, Crown W, Noseworthy P, Yao X, Shah ND, Ross JS, Lyon TD. Wallach JD, et al. JAMA Netw Open. 2021 Oct 1;4(10):e2130587. doi: 10.1001/jamanetworkopen.2021.30587. JAMA Netw Open. 2021. PMID: 34677594 Free PMC article.
OBJECTIVE: To use electronic health record and administrative claims data to emulate the ongoing PRONOUNCE trial (A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease). ...Among 2226 pro …
OBJECTIVE: To use electronic health record and administrative claims data to emulate the ongoing PRONOUNCE trial (A Trial Comparing Cardiova …
Successes and failures of uterine leiomyoma drug discovery.
Ali M, Chaudhry ZT, Al-Hendy A. Ali M, et al. Expert Opin Drug Discov. 2018 Feb;13(2):169-177. doi: 10.1080/17460441.2018.1417381. Epub 2017 Dec 18. Expert Opin Drug Discov. 2018. PMID: 29254389 Review.
Because of this, conservative medical therapies have become an attractive and prior option for those women. Leuprolide acetate (LA), a gonadotropin-releasing hormone (GnRH) agonist, is the only pharmacological agent currently approved for the short-term and pre-operative m …
Because of this, conservative medical therapies have become an attractive and prior option for those women. Leuprolide acetate (LA), …
Clinical pharmacokinetics of depot leuprorelin.
Periti P, Mazzei T, Mini E. Periti P, et al. Clin Pharmacokinet. 2002;41(7):485-504. doi: 10.2165/00003088-200241070-00003. Clin Pharmacokinet. 2002. PMID: 12083977 Review.
3,763 results